Mariana Cornelia Tilinca

Prof. Dr. Mariana Cornelia Tilinca


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2021 in Medicina
Verified
Journal Article
Open access
PDF file
MTMariana Cornelia Tilinca
Mariana Cornelia Tilinca
RTRobert Aurelian Tiuca
Robert Aurelian Tiuca
Alexandru BurlacuAlexandru Burlacu
Alexandru Burlacu
Andreea VARGAAndreea VARGA
Andreea VARGA
Obesity and type 2 diabetes mellitus have become a significant public health problem in the past decades. Their prevalence is increasing worldwide each year, greatly impacting the economic and personal aspects, mainly because they frequently coexist, where the term “diabesity” may be used. The drug class of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is one of the most modern therapy options in managing these metabolic disorders. This review focuses on the effects of liraglutide, a long-acting GLP-1 RA, in diabesity and non-diabetic excess weight. This drug class improves glycemic control by enhancing insulin secretion from the beta-pancreatic cells and inhibiting glucagon release. Furthermore, other effects include slowing gastric emptying, increasing postprandial satiety, and reducing the appetite and food consumption by influencing the central nervous system, with weight reduction effects. It also reduces cardiovascular events and has positive effects on blood pressure and lipid profile. A lower-dose liraglutide (1.2 or 1.8 mg/day) is used in patients with diabetes, while the higher dose (3.0 mg/day) is approved as an anti-obesity drug. In this review, we have summarized the role of liraglutide in clinical practice, highlighting its safety and efficacy as a glucose-lowering agent and a weight-reduction drug in patients with and without diabetes.

29 April 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
ASAndreea Sălcudean
Andreea Sălcudean
DCDora Mihalea Cimpian
Dora Mihalea Cimpian
RPRamona Amina Popovici
Ramona Amina Popovici
Norina Consuela FornaNorina Consuela Forna
Norina Consuela Forna
CDCorodan Comiati Mihaela Diana
Corodan Comiati Mihaela Diana
DMDaniela-Lucia Muntean
Daniela-Lucia Muntean
Adolescence represents a critical developmental stage where diet, gut microorganisms, and mental health are strongly interconnected. The current literature evidences the bidirectional role between dietary habits and psychological well-being, which is mediated by the gut–brain axis. The purpose of this review is to highlight the importance of dietary habits in adolescence period and the impact of different food choices on microbiota and secondary on mental health. Gut microbiota plays a vital role in the synthesis of neurotransmitters such as serotonin, dopamine, noradrenaline, and metabolites like short-chain fatty acids (SCFAs). The disruption in the composition of microbiota is called dysbiosis, which has been associated with a systemic inflammation state and chronic stress. They contribute to the onset of psychiatric disorders including MDD, anxiety, ADHD, and autism. Diets with a high quantity of sugar and low fiber contribute to alteration of microbiota and poor mental health. Additionally, early-life stress, antibiotic usage, and chronic inflammation may alter bacterial communities, with long-term implications for adolescents mental health. Dietary interventions, including the intake of prebiotics, probiotics, SCFAs, and micronutrients could restore microbial balance and improve psychiatric symptoms. This literature review highlights the critical role of diet and gut microbiota for adolescent mental health and emphasizes the need for integrative strategies to promote psychological resilience through microbiome regulation.

3 September 2023 in Life
Verified
Journal Article
Open access
PDF file
AMAdrian Vasile Muresan
Adrian Vasile Muresan
TATomac Andrei Alexandru
Tomac Andrei Alexandru
DODiana Roxana Opris
Diana Roxana Opris
BBBogdan Corneliu Bandici
Bogdan Corneliu Bandici
CCCătălin Mircea Coșarcă
Cătălin Mircea Coșarcă
MTMariana Cornelia Tilinca
Mariana Cornelia Tilinca
Background: peripheral arterial disease (PAD) is identified late in diabetic patients because, in the majority of cases, it is associated with diabetic peripheral neuropathy, resulting in little or no symptoms, or symptoms that are completely neglected. Methods: In this study were enrolled all patients over 18 years of age, with diabetes mellitus type II for more than a year with poor glycemic control, diagnosed with diabetic polyneuropathy admitted to the Diabetology Department, Emergency County Hospital of Targu Mures, Romania between January 2020 and March 2023. We divided the patients into two groups, based on the presence or absence of subclinical atherosclerosis in the lower limb, named “SA” and “non-SA”. Results: Patients in the SA group were older (p = 0.01) and had a higher incidence of IHD (p = 0.03), history of MI (p = 0.02), and diabetic nephropathy (p = 0.01). Moreover, patients with subclinical atherosclerosis had a higher BMI (p < 0.0001) and a longer duration of diabetes (p < 0.0001). Among all patients, the systemic inflammatory markers, MLR (r = 0.331, p < 0.001), NLR (r = 0.517, p < 0.001), PLR (r = 0.296, p < 0.001), SII (r = 0.413, p < 0.001), as well as BMI (r = 0.241, p < 0.001) and HbA1C (r = 0.489, p < 0.001), demonstrated a strong positive correlation with the diabetes duration. The multivariate logistic regression analysis showed that older patients (OR: 2.58, p < 0.001), the male gender (OR: 2.30, p = 0.006), a higher baseline levels of BMI (OR: 7.71, p < 0.001), and the duration of diabetes (OR: 8.65, p < 0.001) are predictors of subclinical atherosclerosis in DN patients. Additionally, the high baseline levels of all systemic inflammatory markers (for all: p < 0.001) and poor diabetes management (OR: 10.4, p < 0.001 for HbA1C; OR: 10.78, p < 0.001 for admission glucose) are independent predictors of SA. Conclusions: the inflammatory markers, NLR, MLR, PLR, and SII, being cheap and easy to collect in routine medical practice from the standard blood tests, could be an important step in predicting vascular outcomes in diabetic patients and the disease’s progression, playing a key role in follow-up visits in type-2 diabetic patients and PAD patients.

25 November 2021 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
MTMariana Cornelia Tilinca
Mariana Cornelia Tilinca
RTRobert Aurelian Tiuca
Robert Aurelian Tiuca
IOAN TILEAIOAN TILEA
IOAN TILEA
Andreea VARGAAndreea VARGA
Andreea VARGA
Diabetes mellitus (DM) represents a major public health problem, with yearly increasing prevalence. DM is considered a progressive vascular disease that develops macro and microvascular complications, with a great impact on the quality of life of diabetic patients. Over time, DM has become one of the most studied diseases; indeed, finding new pharmacological ways to control it is the main purpose of the research involved in this issue. Sodium–glucose cotransporter 2 inhibitors (SGLT-2i) are a modern drug class of glucose-lowering agents, whose use in DM patients has increased in the past few years. Besides the positive outcomes regarding glycemic control and cardiovascular protection in DM patients, SGLT-2i have also been associated with metabolic benefits, blood pressure reduction, and improved kidney function. The recent perception and understanding of SGLT-2i pathophysiological pathways place this class of drugs towards a particularized patient-centered approach, moving away from the well-known glycemic control strategy. SGLT-2i have been shown not only to reduce death from cardiovascular causes, but also to reduce the risk of stroke and heart failure hospitalization. This article aims to review and highlight the existing literature on the effects of SGLT-2i, emphasizing their role as oral antihyperglycemic agents in type 2 DM, with important cardiovascular and metabolic benefits.

Verified
Journal Article
Open access
PDF file
OAOrsolya-Zsuzsa Akácsos-Szász
Orsolya-Zsuzsa Akácsos-Szász
SPSándor Pál
Sándor Pál
KNKinga-Ilona Nyulas
Kinga-Ilona Nyulas
ENEniko Nemes-Nagy
Eniko Nemes-Nagy
AFAna-Maria Fárr
Ana-Maria Fárr
ZSZsuzsánna Simon-Szabó
Zsuzsánna Simon-Szabó
Chronic inflammation and endothelium dysfunction are present in diabetic patients. COVID-19 has a high mortality rate in association with diabetes, partially due to the development of thromboembolic events in the context of coronavirus infection. The purpose of this review is to present the most important underlying pathomechanisms in the development of COVID-19-related coagulopathy in diabetic patients. The methodology consisted of data collection and synthesis from the recent scientific literature by accessing different databases (Cochrane, PubMed, Embase). The main results are the comprehensive and detailed presentation of the very complex interrelations between different factors and pathways involved in the development of arteriopathy and thrombosis in COVID-19-infected diabetic patients. Several genetic and metabolic factors influence the course of COVID-19 within the background of diabetes mellitus. Extensive knowledge of the underlying pathomechanisms of SARS-CoV-2-related vasculopathy and coagulopathy in diabetic subjects contributes to a better understanding of the manifestations in this highly vulnerable group of patients; thus, they can benefit from a modern, more efficient approach regarding diagnostic and therapeutic management.

Verified
Journal Article
Open access
PDF file
MSMónika Szilveszter
Mónika Szilveszter
SPSándor Pál
Sándor Pál
ZSZsuzsánna Simon-Szabó
Zsuzsánna Simon-Szabó
OAOrsolya-Zsuzsa Akácsos-Szász
Orsolya-Zsuzsa Akácsos-Szász
MMMihály Moldován
Mihály Moldován
ENEniko Nemes-Nagy
Eniko Nemes-Nagy
The course of COVID-19 is highly dependent on the associated cardiometabolic comorbidities of the patient, which worsen the prognosis of coronavirus infection, mainly due to systemic inflammation, endothelium dysfunction, and thrombosis. A search on the recent medical literature was performed in five languages, using the PubMed, Embase, Cochrane, and Google Scholar databases, for the review of data regarding the management of patients with a high risk for severe COVID-19, focusing on the associated coagulopathy. Special features of COVID-19 management are presented, based on the underlying conditions (obesity, diabetes mellitus, and cardiovascular diseases), emphasizing the necessity of a modern, holistic approach to thromboembolic states. The latest findings regarding the most efficient therapeutic approaches are included in the article, offering guidance for medical professionals in severe, complicated cases of SARS-CoV-2 infection. We can conclude that severe COVID-19 is closely related to vascular inflammation and intense cytokine release leading to hemostasis disorders. Overweight, hyperglycemia, cardiovascular diseases, and old age are important risk factors for severe outcomes of coronavirus infection, involving a hypercoagulable state. Early diagnosis and proper therapy in complicated SARS-CoV-2-infected cases could reduce mortality and the need for intensive care during hospitalization in patients with cardiometabolic comorbidities.